Entera Bio and OPKO Health announce positive pharmacokinetic results for their oral GLP-2 peptide tablet research for short bowel syndrome.
Entera Bio and OPKO Health announce positive pharmacokinetic results for their collaborative research combining a proprietary long-acting GLP-2 agonist with Entera's N-Tab technology. The program aims to develop an oral GLP-2 peptide tablet alternative for short bowel syndrome and related disorders, which currently require daily injections. The companies completed a PoC single-dose pharmacokinetic study in rodents.
March 20, 2024
3 Articles